News

Researchers have created a novel formulation of pramipexole — the active agent in Mirapex — that can be administered via a film placed on the inside of the cheek. The new formulation may make treatment easier for people with Parkinson’s disease who have trouble swallowing, scientists said in…

A new device, worn like a wristwatch to help control tremor in people with Parkinson’s disease, is now available in the U.S. from its developer, Cala Health. Called the Cala kIQ System, the wearable device is the first to be cleared by the U.S. Food and Drug Administration…

Combining a singing program with conventional speech therapy could help to lessen the vocal problems facing people with Parkinson’s disease, according to findings from a small clinical trial. Therapy sessions were conducted using smartphones, and given to patients at the home. The study, “Voice improvement following…

Certain experiences particular to women, from a natural childbirth or pregnancy-related depression to a hysterectomy, could cause their Parkinson’s disease symptoms to be more severe, an exploratory U.S. study suggests. As noted by it authors, the study “sets the groundwork for acknowledging the role [women specific health factors] ……

NeuroOne Medical Technologies is seeking approval from the U.S. Food and Drug Administration (FDA) for its OneRF ablation system, which aims to remove select regions of brain tissue as a way of treating neurological conditions like Parkinson’s disease. The company submitted its request in the form of…

A grant from the Michael J. Fox Foundation for Parkinson’s Research (MJFF) will allow Icometrix — a company focused on artificial intelligence (AI) solutions for treating disease — to further advance its work on early biomarkers of Parkinson’s in brain magnetic resonance imaging (MRI) scans. “With this research, we…

To assist Synapticure in advancing its nationwide telehealth offerings, the Michael J. Fox Foundation (MJFF) helped the company establish an advisory board of people with Parkinson’s disease and their care partners, and it will help to inform Synapticure’s patients of opportunities to participate in clinical research.

Enrollment is now complete for a Phase 3 trial of buntanetap, an oral therapy candidate from Annovis Bio that aims to improve cognitive and motor skills in early-stage Parkinson’s disease, the company has announced. Since the first participant was dosed in August 2022, more than 640 patients…

Kynmobi (apomorphine hydrochloride), an under-the-tongue therapy approved to help manage off episodes in Parkinson’s disease, is being discontinued in the U.S. as of June 30. Sunovion, which developed the treatment, is voluntarily withdrawing the drug from the U.S. market “due to limited utilization,” according to an announcement…

A grant from the Robert W. Woodruff Foundation to the Parkinson’s Foundation will expand PD GENEration genetic testing and counseling opportunities for African Americans with Parkinson’s disease in Georgia. Through a partnership with the Morehouse School of Medicine, the funding also will support efforts to boost participation…